Paul Hastings LLP advised Viking Therapeutics in its underwritten public offering of its common stock with gross proceeds of approximately $287.5 million. Viking intends to use the net proceeds from the offering for continued development of its VK2809, VK2735, AND VK0214 programs and for general research and development, working capital, and general corporate purposes.

Viking Therapeutics, Inc. (Nasdaq: VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.

Partners Jeff Hartlin and Samantha Eldredge led the Paul Hastings team, which also included associates Jenna Barba and Kelly Go.

More details on the transaction can be found here.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment and real estate, Paul Hastings is a premier law firm providing superior intellectual capital and execution globally to the world’s leading investment banks, asset managers and corporations.